RT 234 inhalation - Respira Therapeutics

Drug Profile

RT 234 inhalation - Respira Therapeutics

Alternative Names: RT234 AOS™ DPI; RT234™

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Respira Therapeutics
  • Developer Respira Therapeutics; United Therapeutics Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Pulmonary hypertension

Most Recent Events

  • 12 Apr 2017 Preclinical trials in Idiopathic pulmonary fibrosis in USA (Inhalation)
  • 12 Apr 2017 Preclinical trials in Pulmonary arterial hypertension in USA (Inhalation)
  • 12 Apr 2017 Preclinical trials in Pulmonary hypertension in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top